Old Web
English
Sign In
Acemap
>
authorDetail
>
James Hao
James Hao
Takeda Pharmaceutical Company
Hereditary angioedema
Medicine
Tolerability
Anesthesia
Adverse effect
4
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
2021
Allergy
Aleena Banerji
Jonathan A. Bernstein
Douglas T. Johnston
William R. Lumry
Markus Magerl
Marcus Maurer
Inmaculada Martinez-Saguer
Andrea Zanichelli
James Hao
Neil Inhaber
Ming Yu
Marc A. Riedl
Help Ole Investigators
Show All
Source
Cite
Save
Citations (2)
Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema.
2021
Pediatric Allergy and Immunology
Henriette Farkas
Avner Reshef
Teresa Caballero
María C. Ortega López
Aharon Kessel
Moshe Y. Vardi
James Hao
Werner Aberer
Show All
Source
Cite
Save
Citations (0)
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
2020
Allergy
Marc A. Riedl
Marcus Maurer
Jonathan A. Bernstein
Aleena Banerji
Hilary Longhurst
H. Henry Li
Peng Lu
James Hao
Salome Juethner
William R. Lumry
Show All
Source
Cite
Save
Citations (8)
Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study
2019
Allergology International
Michihiro Hide
Atsushi Fukunaga
Junichi Maehara
Kazunori Eto
James Hao
Moshe Y. Vardi
Yuji Nomoto
Show All
Source
Cite
Save
Citations (5)
1